ACAAI 2022: Tezepelumab Treatment Cuts Exacerbations With Severe Asthma
Fewer exacerbations seen with tezepelumab compared with the 12 months before initiating treatment and versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.